Patricia Delaite is AMAL’s Chief Medical Officer.
Patricia is a physician with ten years in academic clinical management of patients followed by fifteen years in biopharmaceutical R&D with managerial experience in drug development.
She has a broad scientific and medical expertise in Oncology, Internal Medicine and Drug Development. She has been leading cross-functional teams, Key Opinion Leaders and Health Authorities relationships within different therapeutic areas (Oncology, Onco-hematology). Patricia’s current experience in managing Clinical development (teams/programs/portfolio of projects) within an international matrix organisation was built through different assignments and roles with recognised companies like Novartis, Eli Lilly or Ariad Pharmaceuticals.
In her last position, Patricia was Executive Medical Director at Incyte Biosciences International where she designed and led an immune-modulating agent full clinical development program targeting a parallel global registration.